Pediatric Patients With Sickle Cell Disease at a Public Hospital: Nutrition, Compliance and Early Experience With L-Glutamine Therapy

被引:2
|
作者
Gotesman, Moran [1 ,2 ]
Elgar, Guy [2 ]
Santiago, Laura Hernandez [3 ]
Alvarez, Abigail [1 ]
Pak, Youngju [2 ]
Lin, Henry J. [1 ,2 ]
Lasky, Joseph L. [4 ]
Panosyan, Eduard H. [1 ,2 ]
机构
[1] Harbor UCLA Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, Torrance, CA 90509 USA
[2] Lundquist Inst Biomed Innovat, Torrance, CA USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Cure 4 Kids Fdn, Div Pediat Hematol Oncol, Las Vegas, NV USA
来源
IN VIVO | 2022年 / 36卷 / 04期
关键词
Sickle cell disease; L-glutamine; nutrition; CHILDREN; GROWTH;
D O I
10.21873/invivo.12889
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background/Aim: Hydration and hydroxyurea (HU) can modify sickle cell disease (SCD) severity. Optimal nutrition and L-glutamine (Gln) may provide further amelioration. Patients and Methods: Reviews of medical records and nutrition surveys were used to investigate severity of pediatric patients with SCD in relation to nutrition, growth, hematologic parameters, and disease-modifying agents. Results: Among 25 females and 25 males (9.1 +/- 7 years), beta-globin genotypes were: HbSS/S beta(0), 60%; HbSC, 32%; HbS beta(+), 8%. The mean number of annual pain crises (APC) was 0.97 +/- 1.1. APCs increased >= 2-fold as HbF dropped to <10% with age. Proper hydration and nutrition correlated with younger ages and fewer APCs. Height and weight Z-scores were <=-1SD in 20% of 35 surveyed patients (12 +/- 7.8 years), who had more APCs (2.5 +/- 2.5 vs. 1 +/- 1.3, p=0.03). Prealbumin levels were overall low. Twenty-two of 28 patients on HU reported >= 90% adherence - with higher mean corpuscular volume (92 +/- 9.6 vs. 74 +/- 10 f/l, p<0.01). Seventy percent of Gln prescriptions were filled. Compliance over 23 months was >= 70% in 12 patients, including 2 on chronic transfusion. Of 10 evaluable patients, 6 (8.8 +/- 2.2 years) had fewer APCs with Gln (mean 0.2 vs. 0.9, p=0.016), with increasing prealbumin levels (14.1 to 15.8 mg/dl, p=0.1). Conclusion: Younger, and well-nourished, well-hydrated patients have a milder clinic course. Disease severity was the worse in undernourished teenagers with suboptimal compliance. L-Glutamine with prealbumin monitoring should be considered for further evaluation in SCD.
引用
收藏
页码:1761 / 1768
页数:8
相关论文
共 50 条
  • [1] Pediatric Patients with Sickle Cell Disease at Harbor-UCLA & Early Experience of L-Glutamine Therapy
    Gotesman, Moran
    Elgar, Guy
    Pak, Youngju
    Santiago, Laura Hernandez
    Alvarez, Abigail
    Lin, Henry
    Lasky, Joseph L., III
    Panosyan, Eduard H.
    [J]. BLOOD, 2020, 136
  • [2] L-Glutamine in sickle cell disease
    Cox, S. E.
    Hart, E.
    Kirkham, F. J.
    Stotesbury, H.
    [J]. DRUGS OF TODAY, 2020, 56 (04) : 257 - 268
  • [3] L-Glutamine and the Dawn of Combination Therapy for Sickle Cell Disease
    Minniti, Caterina P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (03): : 292 - 294
  • [4] Rheological Effects of L-Glutamine in Patients with Sickle Cell Disease
    Kanne, Celeste K.
    Reddy, Varun
    Sheehan, Vivien A.
    [J]. BLOOD, 2019, 134
  • [5] L-Glutamine approved for use in patients with sickle cell disease
    Ali, Syed Ibaad
    Akhter, Rimsha
    Khan, Ariba
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2018, 68 (03) : 507 - 507
  • [6] L-Glutamine (Endari) for Sickle Cell Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1539): : 21 - 22
  • [7] L-glutamine for sickle cell disease: Knight or pawn?
    Sadaf, Alina
    Quinn, Charles T.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 245 (02) : 146 - 154
  • [8] L-glutamine therapy improves minute ventilation of sickle cell anemia patients
    Macan, Henry R.
    Porszasz, Janos
    Tsurugaya, Hideki
    Razon, Rafael L.
    Koh, Han
    Casaburi, Richard
    Tanaka, Kouichi R.
    Niihara, Yutaka
    [J]. BLOOD, 2007, 110 (11) : 13B - 13B
  • [9] A Phase 3 Trial of L-Glutamine in Sickle Cell Disease
    Guddati, A. Kumar
    Kota, Vamsi
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1879 - 1879
  • [10] A Phase 3 Trial of L-Glutamine in Sickle Cell Disease
    Niihara, Yutaka
    Miller, Scott T.
    Kanter, Julie
    Lanzkron, Sophie
    Smith, Wally R.
    Hsu, Lewis L.
    Gordeuk, Victor R.
    Viswanathan, Kusum
    Sarnaik, Sharada
    Osunkwo, Ifeyinwa
    Guillaume, Edouard
    Sadanandan, Swayam
    Sieger, Lance
    Lasky, Joseph L.
    Panosyan, Eduard H.
    Blake, Osbourne A.
    New, Tamara N.
    Bellevue, Rita
    Tran, Lan T.
    Razon, Rafael L.
    Stark, Charles W.
    Neumayr, Lynne D.
    Vichinsky, Elliott P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (03): : 226 - 235